Study will assess safety and effectiveness of treatment that restores adequate blood flow in legs of patients to reduce repeat revascularizations and amputations of major lower limbs
Philips Announces First U.S. Patient Enrolled in ILLUMENATE Study of Stellarex 0.014 Drug-Coated Balloon for BTK PAD
Safety and efficacy results presented during late-breaking clinical trials session at VIVA 2018
FRANKLIN LAKES, N.J. (Nov. 7, 2018) – BD (Becton, Dickinson and Company) announced the safety and efficacy data from the LUTONIX® Drug-Coated Balloon (DCB) IDE, level 1 clinical trial for a below-the-knee (BTK) indication.